Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.66 |
| ▸ | ESR1 | P03372 | 4/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.58 |
| ▸ | MAOA | P21397 | 3/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.58 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | BCL2 | P10415 | 6/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 6/20 | 0.51 |
| ▸ | ELANE | P08246 | 3/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | CDK4 | P11802 | 2/20 | 0.46 |
| ▸ | CCND1 | P24385 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | APEX1 | P27695 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31237387 | 1.00 | TTR (0.66) | TTRESR1ESR2MAOAMAOB | |
| Rubiadin SCHEMBL29665059 | 0.85 | BCL2 (0.71) | TTRMAOAMAOBLCKBCL2 | |
| Rubiadin SCHEMBL22616292 | 0.85 | BCL2 (0.71) | TTRMAOAMAOBLCKBCL2 | |
| Rubiadin SCHEMBL30260037 | 0.85 | BCL2 (0.71) | TTRMAOAMAOBLCKBCL2 | |
| Rubiadin SCHEMBL1426928 | 0.85 | BCL2 (0.71) | TTRMAOAMAOBLCKBCL2 | |
| SCHEMBL16226647 | 0.82 | ALDH1A1 (0.52) | TTRESR1ESR2MAOAMAOB | |
| SCHEMBL29066488 | 0.82 | ACLY (0.52) | TTRLCKBCL2MCL1ELANE | |
| SCHEMBL17867452 | 0.81 | MEN1 (0.61) | TTRMAOAMAOBLCKBCL2 | |
| SCHEMBL10909335 | 0.80 | ELANE (0.72) | TTRESR1ESR2MAOAMAOB | |
| SCHEMBL29614714 | 0.80 | ELANE (0.72) | TTRESR1ESR2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118858455-A | Method for measuring anthraquinone component content in madder and application | 广东一方制药有限公司 | 2024-10-29 | — | — | CN | claimed |
| CN-116548443-A | Application of natural quinone-containing compound in preparation of anti-plant virus agent and plant virus agent | 西北农林科技大学 | 2023-08-08 | — | — | CN | claimed |
| CN-112014481-B | Detection method of raw white oral liquid fingerprint spectrum | 湖北梦阳药业股份有限公司 | 2022-10-25 | — | — | CN | claimed |
| CN-112007114-B | Medicine for treating leucopenia and preparation method and application thereof | 湖北梦阳药业股份有限公司 | 2022-05-13 | — | — | CN | claimed |
| EP-3943085-A2 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH Zurich (CH) | 2022-01-26 | — | — | EP | claimed |
| US-20210186947-A1 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH ZURICH (CH) | 2021-06-24 | — | — | US | claimed |
| EP-3801507-A2 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH Zurich (CH) | 2021-04-14 | — | — | EP | claimed |
| WO-2020238420-A1 | DRUG FOR TREATING LEUKOPENIA, PREPARATION METHOD THEREFOR AND USE THEREOF | 湖北梦阳药业股份有限公司 | 2020-12-03 | — | — | WO | claimed |
| CN-112007114-A | Medicine for treating leucopenia and preparation method and application thereof | 湖北梦阳药业股份有限公司 | 2020-12-01 | — | — | CN | claimed |
| EP-3888670-B1 | DRUG FOR TREATING LEUKOPENIA, PREPARATION METHOD THEREFOR AND USE THEREOF | MONYAN PHARMACEUTICAL CO LTD (CN) | 2025-12-24 | — | — | EP | disclosed |
| CN-118858455-B | Method for measuring anthraquinone component content in madder and application | 广东一方制药有限公司 | 2025-11-07 | — | — | CN | disclosed |
| CN-116548443-B | Application of natural quinone-containing compound in preparation of anti-plant virus agent and plant virus agent | 西北农林科技大学 | 2024-11-05 | — | — | CN | disclosed |
| CN-116548443-B | Application of natural quinone-containing compound in preparation of anti-plant virus agent and plant virus agent | 西北农林科技大学 | 2024-11-05 | — | — | CN | disclosed |
| CN-118858455-A | Method for measuring anthraquinone component content in madder and application | 广东一方制药有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20210186947-A1 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH ZURICH (CH) | 2021-06-24 | — | — | US | disclosed |
| EP-3801483-A1 | COMPOSITIONS AND METHODS FOR TREATING STEROID HORMONE-RELATED DISEASES OR DISORDERS | Yale University (US) | 2021-04-14 | — | — | EP | disclosed |
| EP-3801507-A2 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | ETH Zurich (CH) | 2021-04-14 | — | — | EP | disclosed |
| CN-112437660-A | Compositions and methods for treating steroid hormone related diseases or disorders | 耶鲁大学 | 2021-03-02 | — | — | CN | disclosed |
| WO-2020238420-A1 | DRUG FOR TREATING LEUKOPENIA, PREPARATION METHOD THEREFOR AND USE THEREOF | 湖北梦阳药业股份有限公司 | 2020-12-03 | — | — | WO | disclosed |
| CN-112007114-A | Medicine for treating leucopenia and preparation method and application thereof | 湖北梦阳药业股份有限公司 | 2020-12-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210186947-A1 | TOMM6-INTERACTING EXTRACTS AND COMPOUNDS FOR USE IN THE TREATMENT AND PROPHYLAXIS OF NERVOUS SYSTEM DISEASES, ATHEROSCLEROSIS, HEPATITIS B INFECTION AND HUMAN PAPILLOMA VIRUS (HPV) INFECTION | TOMM70, TOMM34, TIMM50 | TTR 3357/4885ESR1 1720/4885ESR2 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.